Research Paper|Volume 16, Issue 3|pp 2866—2886

Comprehensive analysis of cellular senescence and immune microenvironment in papillary thyroid carcinoma

Yinde Huang^1,², Han Jiang¹, Guangwen Xu¹, Xin Li¹, Wenbin Chen¹, Yu Lun¹, Jian Zhang¹

¹Department of Vascular and Thyroid Surgery, The First Affiliated Hospital of China Medical University, Shen-Yang 110001, Liaoning, China
²Department of Breast and Thyroid Surgery, Chongqing General Hospital, Chongqing 401147, China

* Equal contribution

Received: May 11, 2023Accepted: December 22, 2023Published: February 7, 2024

https://doi.org/10.18632/aging.205520

Copyright: © 2024 Huang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Senescence-induced therapy was previously considered as an effective treatment for tumors, and cellular senescence was initially regarded as an effective mechanism against cancer. However, whether cell senescence-related genes can be used to predict the prognosis of papillary thyroid carcinoma (PTC) and immunotherapy remains unclear. We developed and validated a cell senescence-related signature (CSRS) by analyzing the gene expression of 278 genes related to cellular senescence in 738 patients with PTC. Additionally, further analysis showed that CSRS was a reliable predictor of patient outcomes in combination with immune checkpoint expression and drug susceptibility, and patients with high risk scores may benefit from immunotherapy. The findings of this study demonstrate that CSRS serves as an immunotherapeutic response and prognosis biomarker affecting the tumor immune microenvironment of PTC.